Shire Plc - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Shire Plc - Product Pipeline Review - 2016', provides an overview of the Shire Plc's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Shire Plc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Shire Plc - The report provides overview of Shire Plc including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Shire Plc's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Shire Plc's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Shire Plc's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Shire Plc - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Shire Plc's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 8 List of Figures 8 Shire Plc Snapshot 9 Shire Plc Overview 9 Key Information 9 Key Facts 9 Shire Plc - Research and Development Overview 10 Key Therapeutic Areas 10 Shire Plc - Pipeline Review 14 Pipeline Products by Stage of Development 14 Pipeline Products - Monotherapy 15 Pipeline Products - Partnered Products 16 Partnered Products/Combination Treatment Modalities 17 Pipeline Products - Out-Licensed Products 18 Out-Licensed Products/Combination Treatment Modalities 19 Shire Plc - Pipeline Products Glance 20 Shire Plc - Late Stage Pipeline Products 20 Pre-Registration Products/Combination Treatment Modalities 20 Phase III Products/Combination Treatment Modalities 21 Shire Plc - Clinical Stage Pipeline Products 22 Phase II Products/Combination Treatment Modalities 22 Phase I Products/Combination Treatment Modalities 23 Shire Plc - Early Stage Pipeline Products 24 Preclinical Products/Combination Treatment Modalities 24 Shire Plc - Unknown Stage Pipeline Products 25 Unknown Products/Combination Treatment Modalities 25 Shire Plc - Drug Profiles 26 guanfacine hydrochloride ER 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 lifitegrast 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 parathyroid hormone 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 agalsidase alfa 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 budesonide 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 C1 esterase inhibitor (human) 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 icatibant acetate 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 lanadelumab 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 lisdexamfetamine dimesylate 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 prucalopride succinate 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 SHP-465 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 teduglutide (recombinant) 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 idursulfase 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 maribavir 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 mecasermin rinfabate (recombinant) 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 revexepride 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 SHP-610 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 SHP-625 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 SHP-635 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 SHP-640 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 VP-20621 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 SHP-611 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 SHP-622 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 SHP-623 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 SHP-627 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 volixibat potassium 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 Drugs for Rare Diseases 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 DX-2507 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 DX-4012 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 Gene Therapy to Activate GTP Cyclohydrolase I for Parkinson's Disease 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 HTL-1071 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 Monoclonal Antibodies for Genetic Diseases 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 SC-435 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 SHP-630 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 SHP-637 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 SHP-639 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 SHP-641 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 etiguanfacine 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 Shire Plc - Pipeline Analysis 83 Shire Plc - Pipeline Products by Target 83 Shire Plc - Pipeline Products by Route of Administration 85 Shire Plc - Pipeline Products by Molecule Type 86 Shire Plc - Pipeline Products by Mechanism of Action 87 Shire Plc - Recent Pipeline Updates 89 Shire Plc - Dormant Projects 126 Shire Plc - Discontinued Pipeline Products 128 Discontinued Pipeline Product Profiles 128 NRP-290 128 SPD-452 129 SPD-453 129 SPD-756 129 ALX-0646 129 BMN-185 129 C1 esterase inhibitor (human) 129 CX-516 129 ecallantide 130 HCV-796 130 HGT-1111 130 HGT-2610 130 icatibant acetate 130 isovaleramide 130 lisdexamfetamine dimesylate 130 mesalamine ER 131 metoclopramide hydrochloride 131 ramatercept 131 SHP-557 131 SHP-613 131 SHP-628 131 SPD-491 131 SPD-554 131 SPD-556 132 valrocemide 132 Shire Plc - Company Statement 133 Shire Plc - Locations And Subsidiaries 136 Head Office 136 Other Locations & Subsidiaries 136 Shire Plc - Key Manufacturing Facilities 143 Appendix 144 Methodology 144 Coverage 144 Secondary Research 144 Primary Research 144 Expert Panel Validation 144 Contact Us 144 Disclaimer 145
List of Tables
Shire Plc, Key Information 9 Shire Plc, Key Facts 9 Shire Plc - Pipeline by Indication, 2016 11 Shire Plc - Pipeline by Stage of Development, 2016 14 Shire Plc - Monotherapy Products in Pipeline, 2016 15 Shire Plc - Partnered Products in Pipeline, 2016 16 Shire Plc - Partnered Products/ Combination Treatment Modalities, 2016 17 Shire Plc - Out-Licensed Products in Pipeline, 2016 18 Shire Plc - Out-Licensed Products/ Combination Treatment Modalities, 2016 19 Shire Plc - Pre-Registration, 2016 20 Shire Plc - Phase III, 2016 21 Shire Plc - Phase II, 2016 22 Shire Plc - Phase I, 2016 23 Shire Plc - Preclinical, 2016 24 Shire Plc - Unknown, 2016 25 Shire Plc - Pipeline by Target, 2016 83 Shire Plc - Pipeline by Route of Administration, 2016 85 Shire Plc - Pipeline by Molecule Type, 2016 86 Shire Plc - Pipeline Products by Mechanism of Action, 2016 87 Shire Plc - Recent Pipeline Updates, 2016 89 Shire Plc - Dormant Developmental Projects,2016 126 Shire Plc - Discontinued Pipeline Products, 2016 128 Shire Plc, Other Locations 136 Shire Plc, Subsidiaries 136 Shire Plc, Key Manufacturing Facilities 143
List of Figures
Shire Plc - Pipeline by Top 10 Indication, 2016 11 Shire Plc - Pipeline by Stage of Development, 2016 14 Shire Plc - Monotherapy Products in Pipeline, 2016 15 Shire Plc - Partnered Products in Pipeline, 2016 16 Shire Plc - Out-Licensed Products in Pipeline, 2016 18 Shire Plc - Pipeline by Top 10 Target, 2016 83 Shire Plc - Pipeline by Route of Administration, 2016 85 Shire Plc - Pipeline by Top 10 Molecule Type, 2016 86 Shire Plc - Pipeline Products by Top 10 Mechanism of Action, 2016 87
Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanomRead More...
Global activated carbon market size is likely to be valued at USD 5.3 billion by 2020; as per a new research report by Radiant Insights, Inc. Increase in commercial & residential waste water treatment demand owing to escalation in water prices is antRead More...
Global automotive coatings market size is likely to be valued at USD 27.7 billion by 2022; as per a new research report by Radiant Insights, Inc. Vehicle aesthetics, UV radiation and temperature variation protection and enhance durability are certainRead More...
Global FPGA market is anticipated to be valued at USD 9,882.5 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing demand for customized IC’s is expected to drive the demand. Customized IC’s helps manufacturers to moRead More...
Global 3D scanning market is expected to be valued at USD 4,900.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing need for speedy and precise results with high efficiency is anticipated to drive the industry. 3DRead More...
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.